Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Revenue

In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth. Revenue in the quarter ending December 31, 2023 was $230.04M with 26.75% year-over-year growth.

• Revenue (ttm): $829.25M
• Revenue Growth: +25.62%
• P/S Ratio: 6.10
• Revenue / Employee: $2,223,198
• Employees: 373
• Market Cap: 5.06B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	829.25M	169.14M	25.62%
Dec 31, 2022	660.12M	216.81M	48.91%
Dec 31, 2021	443.31M	175.72M	65.67%
Dec 31, 2020	267.59M	71.60M	36.53%
Dec 31, 2019	195.99M	44.13M	29.06%
Dec 31, 2018	151.86M	-164.75M	-52.04%
Dec 31, 2017	316.61M	169.92M	115.84%
Dec 31, 2016	146.69M	11.63M	8.61%
Dec 31, 2015	135.06M	59.72M	79.28%
Dec 31, 2014	75.33M	20.54M	37.47%
Dec 31, 2013	54.80M	12.47M	29.47%
Dec 31, 2012	42.33M	-13.76M	-24.54%
Dec 31, 2011	56.09M	42.46M	311.67%
Dec 31, 2010	13.62M	-47.19K	-0.35%
Dec 31, 2009	13.67M	4.91M	55.99%
Dec 31, 2008	8.76M	4.96M	130.66%
Dec 31, 2007	3.80M	2.82M	287.02%
Dec 31, 2006	981.75K	854.54K	671.76%
Dec 31, 2005	127.21K	-	-
Dec 31, 2004	0	-	-
Dec 31, 2003	0	-	-
Dec 31, 2002	87.77K	-	-
Dec 31, 2001	-	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.